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ABSTRACT
Objectives: A growing number of prospective clinical tri-
als include economic end points. Recognizing the varia-
tion in methodology and reporting of these studies, the
International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) chartered the Task Force on
Good Research Practices: Randomized Clinical Trials—
Cost-Effectiveness Analysis. Its goal was to develop a
guidance document for designing, conducting, and report-
ing cost-effectiveness analyses conducted as a part of clin-
ical trials.
Methods: Task force cochairs were selected by the ISPOR
Board of Directors. Cochairs invited panel members to
participate. Panel members included representatives from
academia, the pharmaceutical industry, and health insur-
ance plans. An outline and a draft report developed by the
panel were presented at the 2004 International and
European ISPOR meetings, respectively. The manuscript
was then submitted to a reference group for review and
comment.
Results: The report addresses issues related to trial
design, selecting data elements, database design and man-
agement, analysis, and reporting of results. Task force
members agreed that trials should be designed to evaluate
effectiveness (rather than efﬁcacy), should include clinical
outcome measures, and should obtain health resource use
and health state utilities directly from study subjects. Col-
lection of economic data should be fully integrated into
the study. Analyses should be guided by an analysis plan
and hypotheses. An incremental analysis should be con-
ducted with  an intention-to-treat approach. Uncertainty
should be characterized. Manuscripts should adhere to
established standards for reporting results of cost-
effectiveness analyses.
Conclusions: Trial-based cost-effectiveness studies have
appeal because of their high internal validity and timeli-
ness. Improving the quality and uniformity of these stud-
ies will increase their value to decision makers who
consider evidence of economic value along with clinical
efﬁcacy when making resource allocation decisions.
Keywords: cost-effectiveness, economic, guidelines, rand-
omized clinical trial.
Introduction
Clinical trials evaluating medicines, medical
devices, and procedures now commonly assess eco-
nomic value of these interventions. The growing
number of prospective clinical/economic trials
reﬂects both widespread interest in economic infor-
mation for new technologies and the regulatory and
reimbursement requirements of many countries that
now consider evidence of economic value along
with clinical efﬁcacy. In recent years, research has
also improved the methods for the design, conduct,
and analysis of economic data collected alongside
clinical trials. Despite these advances, the literature
reveals a great deal of variation in methodology and
reporting of these studies. Improving the quality of
these studies will enhance the credibility and useful-
ness of cost-effectiveness analyses to decision mak-
ers worldwide.
To foster improvements in the conduct and
reporting of trial-based economic analyses, the
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International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) chartered the ISPOR
Task Force on Good Research Practices: Rand-
omized Clinical Trials-Cost-Effectiveness Analysis
(RCT-CEA). The task force cochairs were selected
by the ISPOR Board of Directors, and the cochairs
invited the other panel members to participate. The
panel was ﬁrst assembled in January 2004, commu-
nicated monthly, and agreed on an outline and pre-
liminary content that was presented for comment
by ISPOR membership at the May 2004 annual
meeting. The draft report was then written and pre-
sented to the ISPOR membership at the October
2004 European meeting. A volunteer reference
group of ISPOR members provided valuable com-
ments on the draft report, which supported the
completion of the ﬁnal report in February 2005.
The purpose of this report is to state the consen-
sus position of this Task Force (Table 1). The goal
for the panel was to develop a guidance document
for the design, conduct, and reporting of cost-
effectiveness analyses alongside clinical trials. The
intended audiences are researchers in academics,
industry, and government who design and imple-
ment these studies, decision makers who evaluate
clinical and economic evidence for formulary and
insurance coverage policies, and students of the
area. The panel recognizes that advances in meth-
odology for joint clinical/economic analyses will
continue and that clinical/economic trials are heter-
ogeneous in nature. Therefore, the report highlights
areas of consensus, emerging methodologies with a
diversity of professional opinions, and issues where
further research and development are needed.
The focus of this report is cost-effectiveness anal-
ysis conducted alongside randomized clinical trials
designed to test the efﬁcacy or effectiveness for
drugs, devices, surgical procedures, or screening
interventions, including pragmatic trials. Clinical
trials are artiﬁcial treatment environments and do
not provide all the economic information needed by
decision makers. Trial populations do not com-
monly reﬂect patient groups treated in clinical prac-
tice, and the time horizon for trials often does not
reﬂect the duration of impact of the intervention.
These issues are commonly addressed with mode-
ling. The reader is referred to an earlier guidance
document addressing these issues [1].
There are also some common issues in cost-
effectiveness analysis that are fundamental to all
studies of this nature that will not be addressed in
this article. These include study perspective, choice
of discount rate for costs and outcomes, type of
analysis (e.g., cost–utility, cost–beneﬁt), types of
costs that will be included (direct medical, nonmed-
ical, etc.), and marginal versus average costing.
These issues apply to all economic analyses, not just
economic studies within clinical trials, and are well
described in the literature.
Initial Trial Design Issues
The quality of economic information that is derived
from trials depends on the attributes of the trial’s
design. Those economic analyses often described
as being conducted “alongside” clinical trials are
indicative of an important practical design issue.
Economic analysis is rarely the primary purpose of
an experimental study. Nevertheless, it is important
that the analyst contributes to the design of the
study to ensure that the structure of the trial will
provide the data necessary for a high quality eco-
nomic study.
Appropriate Trial Design
The distinction between pragmatic and exploratory
trials and the corresponding distinction between
effectiveness and efﬁcacy is well understood [2,3]. It
is generally acknowledged that pragmatic effective-
ness trials are the best vehicle for economic studies;
however, it is usually necessary to undertake eco-
nomic evaluations earlier in the development cycle
where the focus is on efﬁcacy, including phase III or
even phase II drug trials, to provide timely informa-
tion for pricing and reimbursement. Our report is
meant to apply to both types of trials.
Large simple trials [4] are efﬁcient for addressing
clinical questions because they capture the main
effects of treatments that have small to moderate
impacts on large potential populations. They will
also be efﬁcient for answering economic questions
for diseases or treatments where the bulk of costs
derive from primary outcomes that are measured in
the trial and for which the quality of life impacts are
persistent, and thus can be measured infrequently.
An ideal follow-up period for an economic study
is independent of the occurrence of clinical events,
whether study-related or not. All patients should be
followed for a common length of time or the full
duration of the trial. Discontinuation of data col-
lection because of a clinical event will fail to capture
the important aspects of the disease under study: the
adverse effects of the event on quality of life,
resource use, and cost.
Sample Size and Power
In an ideal world, the economic appraisal would be
factored into sample-size calculations using stand-
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ard methods [5,6] based on asymptotic normality,
or by simulation [7]. Nevertheless, it is common for
the sample size of the trial to be based on the pri-
mary clinical outcomes alone. As a consequence, it
is possible that the economic comparisons will be
underpowered. Analysts should calculate the likely
power of the study at the design stage to ascertain
whether, given the proposed sample size, it makes
sense to undertake an economic appraisal. In many
cases, sample-size restrictions will necessitate focus
on estimation rather than hypothesis testing of the
economic outcomes. In cases where researchers
wish to set up formal hypotheses for the economic
analyses, these should be stated a priori including
the thresholds (e.g., $50,000 or $100,000/quality-
adjusted life-year [QALY]) and the power to detect
when incremental analysis meets or exceeds those
thresholds [8].
Study End Points
The choice of primary end point in a clinical study
may not correspond with the ideal end point for
economic evaluation. For example, the use of com-
posite clinical end points is common in clinical trials
(e.g., fatal events and nonfatal events combined) to
provide greater statistical power. Nevertheless, cost
per composite clinical end point is often an unsat-
isfactory summary measure for an economic analy-
sis, in part because the different outcomes are rarely
of equal importance. It is recommended that clinical
end points used in economic evaluations be pre-
sented in disaggregated form. We recommend
weighting end points (e.g., by utilities) so that they
yield a measure of QALYs in the case of cost-effec-
tiveness analysis, or a monetary beneﬁt measure in
the case of cost–beneﬁt analysis. Alternatively, qual-
Table 1 Core recommendations for conducting economic analyses alongside clinical trials
Trial design
Trial design should reﬂect effectiveness rather than efﬁcacy when possible.
Full follow-up of all patients is encouraged.
Describe power and ability to test hypotheses, given the trial sample size.
Clinical end points used in economic evaluations should be disaggregated.
Direct measures of outcome are preferred to use of intermediate end points.
Data elements
Obtain information to derive health state utilities directly from the study population.
Collect all resources that may substantially inﬂuence overall costs; these include those related and unrelated to the intervention.
Database design and management
Collection and management of the economic data should be fully integrated into the clinical data.
Consent forms should include wording permitting the collection of economic data, particularly when it will be gathered from third-party 
databases and may include pre- and/or post-trial records.
Analysis
The analysis of economic measures should be guided by a data analysis plan and hypotheses that are drafted prior to the onset of the study.
All cost-effectiveness analyses should include the following: an intention-to-treat analysis; common time horizon(s) for accumulating costs and 
outcomes; a within-trial assessment of costs and outcomes; an assessment of uncertainty; a common discount rate applied to future costs 
and outcomes; an accounting for missing and/or censored data
Incremental costs and outcomes should be measured as differences in arithmetic means, with statistical testing accounting for issues speciﬁc to 
these data (e.g., skewness, mass at zero, censoring, construction of QALYs).
Imputation is desirable if there is a substantial amount of missing data. Censoring, if present, should also be addressed.
One or more summary measures should be used to characterize the relative value of the intervention. 
Examples include ratio measures, difference measures, and probability measures (e.g., cost-effectiveness acceptability curves).
Uncertainty should be characterized. Account for uncertainty that stems from sampling, ﬁxed parameters such as unit costs and the discount 
rate, and methods to address missing data.
Threats to external validity—including protocol-driven resource use, unrepresentative recruiting centers, restrictive inclusion and exclusion 
criteria, and artiﬁcially enhanced compliance—are best addressed at the design phase.
Multinational trials require special consideration to address intercountry differences in population characteristics and treatment patterns.
When models are used to estimate costs and outcomes beyond the time horizon of the trial, good modeling practices should be followed. 
Models should reﬂect the expected duration of the intervention on costs and outcomes.
Subgroup analyses based on prespeciﬁed clinical and economic interactions, when found to be signiﬁcant ex post, are appropriate. Ad hoc 
subgroup analysis is discouraged.
Reporting the results
Minimum reporting standards for cost-effectiveness analyses should be adhered to for those conducted alongside clinical trials.
The cost-effectiveness report should include a general description of the clinical trial and key clinical ﬁndings.
Reporting should distinguish economic data collected as part of the trial vs. data not collected as part of the trial.
The amount of missing data should be reported. If imputation methods are used, the method should be described.
Methods used to construct and compare costs and outcomes, and to project costs and outcomes beyond the trial period should be described.
The results section should include summaries of resource use, costs, and outcome measures, including point estimates and measures of 
uncertainty. Results should be reported for the time horizon of the trial, and for projections beyond the trial (if conducted).
Graphical displays are recommended for results not easily reported in tabular form (e.g., cost-effectiveness acceptability curves, joint density 
of incremental costs and outcomes).
QALYs, quality-adjusted life-years.
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ity of life values may be obtained within the trial at
regular intervals and the QALYs estimated as one of
the outcomes of the trial.
If possible, one should avoid using intermediate
end points (e.g., percent low-density lipoprotein
reduction) as the measure of beneﬁt; however,
intermediate outcome measures are often employed
when the costs of conducting a long-term trial are
prohibitive. When use of intermediate outcomes is
unavoidable, additional evidence is needed to link
them with long-term costs and outcomes. If such a
link is not reliable or is unavailable, the analyst
should argue for follow-up sufﬁcient to include clin-
ically meaningful disease end points.
Appropriate Follow-up
Economic analyses ideally include lifetime costs and
outcomes of treatment. Nevertheless, clinical trials
rarely extend beyond a few years and are often con-
ducted over much shorter periods. In practice,
consideration of the follow-up period for the trial
involves the relationship between intermediate end
points gathered in the short run and long-term dis-
ease outcomes—the stronger that relationship, the
more a reliance on intermediate end points can be
justiﬁed.
Data Elements
The design issues discussed above will impact deci-
sions about which resource use and outcome meas-
ures to collect, how to collect them, and how to
value them. To begin, we recommend developing a
description of the clinical processes for the interven-
tion and how the intervention may impact resource
use in the short and long term [9]. In this process,
study perspective affects the types of resource use—
both medical and nonmedical—that should be con-
sidered for inclusion in the study. For example, the
societal perspective might include patients’ costs for
transportation; time spent undergoing treatment,
caregiver time, and nonmedical goods and services
attributable to the disease or treatment.
After resources have been identiﬁed, logistical
and cost considerations often require prioritization
as to which data elements will be collected. We rec-
ommend that analysts focus on “big ticket” items as
well as resources that are expected to differ between
treatment arms [10]. For the items chosen, the study
should collect information on all resource use not
just that considered to be disease- or intervention-
related [11,12]. If necessary, the distinction between
costs related and unrelated to the disease can be
attempted at the analysis phase.
For each resource, the level of aggregation
desired should be prospectively determined. As an
example, hospitalizations could be considered in
disaggregated units, such as nursing time, operat-
ing-room time, and supplies, or in highly aggregated
units, such as numbers of hospitalizations or days in
the  hospital.  The  decision  is  typically  driven  by
the characteristics of the intervention under study,
resource use patterns expected, and availability of
unit costs, also called unit prices or price weights.
For practical reasons, the level of aggregation may
be varied by whether the resource use is thought to
be disease- or intervention-related.
In some trial settings, secondary data such as
hospital bills or claims data are available. These
data sources can provide an inexpensive, detailed
accounting of some resources consumed by
patients, and should be used when available [13].
Valuing Resource Use
Unit costs should be consistent with measured
resource use, the study’s perspective, and its time
horizon. For example, if the level of resource aggre-
gation is hospital days that include intensive care
unit (ICU) and non-ICU days, the unit costs should
reﬂect the costs of each type of service [13,14]; if the
study is conducted from the societal perspective,
unit costs should reﬂect social opportunity cost. In
selecting a costing approach, analysts should weigh
issues of accuracy/bias, cost, feasibility, and gener-
alizability [15]. For a more thorough discussion on
costing issues, we refer readers to Drummond et al.
[16] and Luce et al. [9].
Unit cost estimates are rarely derived via direct
observation of patients in trials. Most often they are
derived from substudies that are divorced from the
trial itself. Sometimes, unit costs will be estimated
from trial centers, but more commonly they are
derived from national data [17–20]. If a reliable
method for cost imputation exists (e.g., diagnostic
group weights), one can combine the two methods
by collecting a limited set of unit costs in a number
of countries and imputing the remainder of costs
[21]. Ideally, unit costs to be used for resource cost-
ing should be ﬁnalized prior to unblinding the trial
data.
Because relative costs can affect resource use, in
general one should use unit cost estimates that are
speciﬁc to the precise intervention under study and
speciﬁc events of interest in the trial but which are
generalizable to the population that the study is
intended to inform.
When unit costs from more than one country are
used in an analysis (e.g., the pooled analysis, when
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resource use in a country is multiplied by unit costs
from  that  country),  results  have  to  be  converted
to a common currency if they are to be compared
appropriately. Purchasing power parity adjustments
are recommended for such conversion [22,23].
Selecting and Tracking Measures of Outcomes
Because cost–utility analyses are widely accepted,
we recommend that analysts collect preference
weights as part of clinical trials. The most common
method of assessing preferences is the use of a pref-
erence-weighted health state classiﬁcation system
such as the EuroQol-5D [24,25], one of the three
versions of the Health Utilities Index [26–29], or the
Quality of Well-Being Scale [30]. Analysts may also
consider the inclusion of a rating scale to measure
patient-based preferences [31]. Frequency and tim-
ing of these assessments should capture changes in
patients’  quality  of  life  that  may  be  affected  by
the treatment but will be inﬂuenced by the disease
severity of the study population, the study duration,
the timing of trial visits, and patient burden [32].
Other options for collecting preference data
include direct-elicitation methods such as standard
gamble or time-tradeoff exercises. These methods
have certain theoretical advantages; however, their
use in clinical trials is often difﬁcult. Trained inter-
viewers or computerized applications are routinely
used to conduct such exercises [16,33]. Also, many
respondents have difﬁculty understanding and com-
pleting the exercises [34–36]. Finally, there is some
evidence that these measures are generally unre-
sponsive to changes in health status [37–40]. At
present, the balance between the feasibility and
desirability of using direct-elicitation methods in
clinical trials remains an issue to be decided on a
case-by-case basis.
Database Design and Management
Ideally, collection and management of the economic
data should be fully integrated into the clinical data.
As such, there should be no distinction between the
clinical and economic data elements. As with any
prospective study, there should be a plan for ongo-
ing data  quality  monitoring  to  address  missing
and poor quality data issues immediately. Queries
should be managed on an ongoing basis rather than
at the end of the trial to maximize data complete-
ness and quality, and the timeliness of ﬁnal analysis.
Informed consent for clinical studies does not
routinely include provisions for collection of eco-
nomic data, particularly from third-party data-
bases. Therefore, explicit language should be
included in trial consent documents. The consent
forms should allow for capture of pre- and post-
trial economic data if such data are necessary for
the economic analysis.
Collection of economic data may reveal adverse
events, such as hospitalization, not otherwise found
in the clinical data. Data handling procedures are
necessary to maintain consistency between eco-
nomic and safety databases.
In reality, the clinical analysts are usually sepa-
rate from the economic analysts. The clinical data
elements and data formatting procedures needed for
the economic analysis should be prespeciﬁed such
that transfer of all necessary data for the economics
study is timely and complete.
Analysis
Guiding Principles
The analysis of economic measures should be
guided by a data analysis plan. A prespeciﬁed plan
is particularly important if formal tests of hypoth-
eses are to be performed. Any tests of hypotheses
that are not speciﬁed within the plan should be
reported as exploratory. In addition, the plan
should specify whether regression or other multi-
variable analyses will be used to improve precision
and to adjust for treatment group imbalances. The
plan should also identify any selected subgroups
and state whether a no intention-to-treat analysis
will be conducted.
Although the speciﬁc analytic methods used in
the analysis of resource use, cost, and cost-effective-
ness are likely to differ, there are several analysis
features that should be common to all economic
analyses alongside clinical trials:
• The intention-to-treat population should be
used for the primary analysis.
• A common time horizon(s) should be used for
accumulating costs and outcomes; a within-
trial assessment of costs and outcomes should
be conducted, even when modeling or project-
ing beyond the time horizon of the trial.
• An assessment of uncertainty is necessary for
each measure (standard errors or conﬁdence
intervals for point estimates; P values for
hypothesis tests).
• A (common) real discount rate should be
applied to future costs and, when used in a cost-
effectiveness analysis, to future outcomes.
• If data for some subjects are missing and/or
censored, the analytic approach should address
this issue consistently in the various analyses
affected by missing data.
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Trial Costs
The purpose of clinical trial cost analysis is to esti-
mate costs, cost differences associated with treat-
ment, the variability of differences, and whether the
differences occurred by chance.
Once resources have been identiﬁed and valued,
differences between groups must be summarized.
Arithmetic mean cost differences are generally con-
sidered the most appropriate and robust measure
[41]. Nevertheless, cost data often do not conform
to the assumptions for standard statistical tests for
comparing differences in arithmetic means [42–44].
They are usually right-skewed and truncated at zero
because of small numbers of high-resource-use
patients, many patients who incur no costs, and
the impossibility of incurring costs less than zero.
In most cases, the nonparametric bootstrap is an
appropriate method to compare means and calcu-
late conﬁdence intervals [45,46]. Other common
nonparametric tests (e.g., Wilcoxon) compare
medians and not means and thus are not appropri-
ate [47–49]. Transformations to normalize the dis-
tribution are not straightforward and are often
sensitive to departures from distributional assump-
tions. Retransformation to the original scale of
costs must include transformation of error terms
[50–54].
The same distributional issues that affect univar-
iate tests of costs also affect use of costs as a
dependent variable in a multivariate regression
analysis. The underlying distribution of costs
should be carefully assessed to determine the most
appropriate approach to conduct statistical infer-
ence on the costs between treatment groups [55].
The choice of the multivariate model requires care-
ful consideration: ordinary least squares and gener-
alized linear models perform differently in terms of
bias and efﬁciency of estimation, depending upon
the underlying data distribution [51]. If differences
in resource use or subsets of costs are to be esti-
mated, similar considerations regarding the appro-
priateness of statistical tests based on distributional
assumptions should be applied.
When study participants use large amounts of
medical services that are unrelated to the disease or
treatment under study, it may be difﬁcult to detect
the inﬂuence of the treatment on total health-care
costs. One approach to addressing this problem is
to conduct secondary analyses that evaluate costs
that are considered related to the disease or treat-
ment under study. If such analyses are performed, it
is important to identify services that were deemed
“disease-related” versus those deemed “unrelated,”
and to display costs for each component in the
treatment and control arms.
Outcomes
When one of the trial’s clinical end points is also
used as the outcome for the cost-effectiveness anal-
ysis (e.g., in-trial mortality), it is generally most
transparent to adopt the methods used in the clini-
cal analysis for the primary analysis plan, particu-
larly if the clinical result is cited in product labeling
or a publication. In some cases, the clinical analysis
methods are not appropriate for economic analysis
(e.g., the clinical analysis may focus on relative
treatment differences, while the economic analysis
needs absolute treatment differences); if other out-
comes are used for the economic analysis, the link-
age between the clinical and economic measures
should be clearly speciﬁed. Analyses of outcomes
for the cost-effectiveness study may employ multi-
variable or other methods that are consistent with
the cost analysis or otherwise appropriate for the
data [56–60]. Cost-effectiveness analysis should still
be performed if the clinical study fails to demon-
strate a statistically signiﬁcant difference in clinical
end points. In situations where cost-minimization
analysis is conducted, the analyst should also con-
duct joint analysis of costs and outcomes to convey
information about the likelihood of an intervention
being cost-effective.
Using nonclinical effectiveness end points, such
as QALYs, involves both construction and analysis.
Health state utilities, either collected directly from
trial patients or imputed based on observed health
states, can be transformed into QALYs using stand-
ard area-under-the-curve methods [16,61]; a recent
consideration involves adjusting for changes in
health [62]. Simple analysis of means is the usual
starting point; reﬁnements may include adjusting
for ceiling effects [63] and modeling of longitudinal
effects [64,65].
Missing and Censored Data
Missing data are inevitable in economic analyses
conducted alongside trials. Such data can include
item-level missingness and missingness because of
censoring. In analyzing data sets with missing data,
one must determine the nature of the missing data
and then deﬁne an approach for dealing with the
missing data. Missing data may bear no relation to
observed or unobserved factors in the population
(missing completely at random), may have a rela-
tionship to observed variables (missing at random),
or may be related to unobserved factors (not miss-
ing at random) [66]. Eliminating cases with missing
ISPOR RCT-CEA Task Force Report 527
data is not recommended because it may introduce
bias or severely reduce power to test hypotheses.
Nevertheless, ignoring small amounts of missing
data is acceptable if a reasonable case can be made
that doing so is unlikely to bias treatment group
comparisons.
Imputation refers to replacing missing ﬁelds with
estimates. If one chooses to impute missing data,
most experts recommend multiple imputation
approaches, as they reﬂect the uncertainty that is
inherent when replacing missing data [67–69].
Most commonly used statistical software packages
include programs for imputation of missing data.
A  review  of  these  programs  can  be  found  at
http://www.multiple-imputation.com [70].
Censoring can be addressed with a number of
approaches. Most assume that censoring is either
completely at random [71] or at random [72–76].
Nevertheless, nonrandom censoring is common,
and external data sources for similar patients may
be required to both identify and address it.
Summary Measures
One or more summary measures should be used to
characterize the relative value of the treatments in
the clinical trial. Three general classes of summary
measures are available that differ in how the incre-
mental costs and outcomes are combined into a sin-
gle metric:
• Ratio measures (e.g., incremental cost-effective-
ness ratios) are obtained by dividing the incre-
mental cost by the incremental health beneﬁt.
• Difference measures (e.g., net monetary bene-
ﬁts) rely on the ability to deﬁne a common
metric (such as monetary units) by which both
costs and outcomes can be measured [77–79].
• Probability measures (e.g., acceptability curves)
characterize the likelihood the new treatment
will be deemed cost-effective based on the
incremental costs and outcomes [80,81].
The difference measures and probability meas-
ures are calculated for speciﬁc values of “willing-
ness to pay” or cost-effectiveness thresholds.
Because these values may not be known and/or vary
among health-care decision makers, one should
evaluate the summary measure over a reasonable
range of values.
Uncertainty
Results of economic assessments in trials are subject
to a number of sources of uncertainty, including
sampling uncertainty, uncertainty in parameters
such as unit costs and the discount rate, and—when
missing data are present—imputation-related
uncertainty.
Sampling uncertainty. Because economic outcomes
in trials are the result of a single sample drawn from
the population, one should report the variability in
these outcomes that arises from such sampling.
Variability should be reported for within-group
estimates of costs and outcomes, between-group
differences in costs and outcomes, and the compar-
ison of costs and outcomes. One of the most com-
mon measures of this variability is the conﬁdence
interval.
Policy inferences about adoption of a therapy
should be based on one’s level of conﬁdence that its
cost for a unit of outcome, for example, a QALY, is
less than one’s maximum willingness to pay. Thus,
one should report ranges of ceiling ratios for which
one: 1) is conﬁdent that the therapy is good value
for the cost; 2) is conﬁdent that the therapy is not
good value; and 3) cannot be conﬁdent that the
therapies differ from one another. Policymakers can
then draw inferences by identifying their maximum
willingness to pay and determining into which of
the ranges it falls.
These ranges of ceiling ratios where one can and
cannot be conﬁdent about a therapy’s value can be
calculated by use of conﬁdence intervals for cost-
effectiveness ratios [82,83], conﬁdence intervals for
net monetary beneﬁt, or the acceptability curve.
One advantage of the conﬁdence interval for the
cost-effectiveness ratio is that its limits directly
deﬁne the boundaries between these ranges. One
advantage of the acceptability curve is that it deﬁnes
the boundaries between these ranges for varying
levels of conﬁdence that range from 0 to 100%.
Parameter  uncertainty. Uncertainty related to
parameter estimates such as unit costs and the dis-
count rate should be assessed by use of sensitivity
analysis. For example, if one uses a discount rate of
3%, one may want to assess the impact of this
assumption by repeating the analysis but using a
1% or a 5% rate. Analysts should evaluate all
parameters that, when varied, have the potential to
inﬂuence policy decisions. Measures of stochastic
uncertainty and sensitivity analysis for parameter
uncertainty are complements, not substitutes. Thus,
when conducting sensitivity analysis, one should
report both the revised point estimate and revised
95% conﬁdence intervals that result from the sen-
sitivity analysis.
Imputation  uncertainty. Finally, some methods
employed to address missing or censored data (e.g.,
Ramsey et al.528
use of an imputed mean) may artiﬁcially reduce esti-
mates of stochastic uncertainty. One should make
efforts to address this shrinkage when reporting sto-
chastic uncertainty, for example, by bootstrapping
the entire imputation and estimation process.
Identifying and Addressing Threats to External 
Validity/Generalizability
Because of the “artiﬁciality” of most clinical trials,
they have high internal, but may have low external
validity. The threats to external validity come from:
• protocol-driven resource use (which could bias
costs in each treatment arm upwards if included
and downwards if excluded, but it is generally
difﬁcult to know how this will bias the differ-
ence between treatments);
• unrepresentative recruiting centers (e.g., large,
urban, academic hospitals);
• inclusion of study sites from countries with
varying access and availability of health-care
services (e.g., rehabilitation, home care, or
emergency services);
• restrictive inclusion and exclusion criteria
(patient population, disease severity,
comorbidities);
• artiﬁcially enhanced compliance.
The external validity can best be increased by
making the trial more naturalistic during the design
phase of the trial [16,84].
Additional threats arise with international trials,
as treatment pathways, patient and health-care pro-
vider behavior, supply and ﬁnancing of health care,
and unit costs (prices) can differ tremendously
between countries [85–92]. Pooled results may not
be representative of any one country, but the sample
size is usually not large enough to analyze countries
separately.
It is common to apply country-speciﬁc unit costs
for pooled trial resource use to estimate country-
speciﬁc costs. In practice, this approach yields few
qualitative differences in summary measures of
cost-effectiveness among countries of similar levels
of economic development but may not adjust for
important country-speciﬁc differences [93,94].
Rather, intercountry differences in population char-
acteristics and treatment patterns are more likely to
inﬂuence summary measures between countries
rather than differences in unit costs. Recommended
approaches to address this issue include [93,95–97]:
• hypothesis tests of homogeneity of results
across countries (and adjusting the resource use
in other countries to better match those seen in
country X);
• multivariate cost or outcome regressions to
adjust for country effects (e.g., include country
dummies or adjusted gross national product per
capita as covariates);
• multilevel random effects model with shrinkage
estimators.
Modeling Beyond the Time Horizon of the Trial
The cost-effectiveness observed within the trial may
be substantially different from what would have
been observed with continued follow-up. Modeling
is used to estimate costs and outcomes that would
have been observed had observation been pro-
longed. When modeling beyond the follow-up
period for the trial, it is important to project costs
and outcomes over the expected duration of treat-
ment and its effects.
Direct modeling of long-term costs and outcomes
is feasible when the trial period is long enough, or if
at least a subset of patients are observed for a longer
time and provide a basis for estimating other
patients’ outcomes. Parametric survival models esti-
mated on trial data are recommended for such pro-
jections. In cases where such direct modeling is not
feasible, it may be possible to “marry” trial data to
long-term observational data in a model. In either
case, good modeling practices should be followed.
The reader is referred to the consensus position of
the ISPOR Task Force on Good Research Prac-
tices—Modeling Studies for discussion of modeling
issues [1].
Cost-effectiveness ratios should be calculated at
various time horizons (e.g., 2, 5, 10 years, or as
appropriate for the disease), both to accommodate
the needs of decision makers and to provide a “tra-
jectory” of summary measures over time. The
effects of long-term health-care costs not directly
related to treatment should be taken into account as
well as possible [98]. As always, assumptions used
must be described and justiﬁed, and the uncertainty
associated with projections must be taken into
account.
Subgroup Analysis
The dangers of spurious subgroup effects are well-
known. For example, the probability of ﬁnding a
difference due solely to random variation increases
with the number of differences examined unless the
alpha-level is scrupulously adjusted. Yet economics
requires a marginal approach, so proper subgroup
analysis can be vital to decision makers. The focus
should be on testing treatment interactions on the
absolute scale, with a justiﬁcation for choice of scale
used. In cases where prespeciﬁed clinical interac-
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tions are signiﬁcant, subgroup analyses may be
justiﬁed. Subgroup analysis based on prespeciﬁed
economic interactions should also be reported.
Reporting the Methods and Results
We anticipate that the results of an economic anal-
ysis will have a variety of audiences. Correspond-
ingly, detailed and comprehensive information on
the methods and results should be readily available
to any interested reader. Journal word limits often
necessitate parsimony in reporting; therefore, we
recommend that detailed technical reports be made
available on the World Wide Web.
A number of organizations have developed min-
imum reporting standards for economic analyses
(e.g., study perspective, discount rate, marginal vs.
average outcomes and analyses) [99,100]. The
principles in these should be adhered to in all eco-
nomic studies. Here, we highlight issues particular
to economic studies conducted alongside clinical
trials.
The report should include these elements:
Trial-Related Issues
• General description of the clinical trial, includ-
ing patient demographics, trial setting (e.g.,
country, tertiary care hospital), inclusion and
exclusion criteria and protocol-driven proce-
dures that inﬂuence external validity, interven-
tion and control arms, and time horizon for the
intervention and follow-up;
• Key clinical ﬁndings.
Data for the Economic Study
• Clear delineation between patient-level data
collected as part of the trial versus data not
collected as part of the trial:
• Trial: health related quality of life survey
instruments, data sources, collection sched-
ule (including the follow-up period), etc.
• Nontrial: unit costs, published utility
weights, etc.
• Amount of missing and censored data.
Methods of Analysis
• Construction of costs and outcomes;
• In cases where the main clinical end point is
used in the denominator of the incremental
cost-effectiveness ratio and different methods
were used to analyze this end point in the clin-
ical and economic analyses, any differences in
the point estimates should be explained;
• Methods for addressing missing and censored
data;
• Statistical methods used to compare resource
use, costs, and outcomes;
• Methods and assumptions used to project costs
and outcomes beyond the trial period;
• Any deviations from the prespeciﬁed analysis
plan and justiﬁcation for these changes.
Results
• Resource use, costs, outcome measures,
including point estimates and measures of
uncertainty;
• Results within the time horizon of the trial;
• Results with projections beyond the trial (if
conducted);
• Graphical displays of results not easily reported
in tabular form (e.g., cost-effectiveness accept-
ability curves, joint density of incremental costs
and outcomes).
When there are economic analyses alongside
several clinical trials for a given intervention,
attempts may be made to estimate a summary cost-
effectiveness ratio across trials (although the meth-
ods for this are not perfectly straightforward, i.e.,
clearly not a simple average of the individual incre-
mental cost-effectiveness ratios). Data from eco-
nomic analyses performed in the context of trials
may also be used in independent cost-effectiveness
models based on decision analysis or meta-analyses
[84]. To facilitate synthesis of economic informa-
tion from multiple trials, authors should report
means and standard errors for the incremental costs
and outcomes and their correlation.
Conclusions
As decision makers increasingly demand evidence of
economic value for health-care interventions, con-
ducting high quality economic analyses alongside
clinical studies is desirable because they provide
timely information with high internal validity. This
ISPOR RCT-CEA Task Force Report is intended to
provide guidance to improve their quality and con-
sistency. The task force recognizes that there are
areas where future methodological research could
further improve the quality and usefulness of these
studies. Examples here include (among many): new
approaches for pooling and analyzing data from
multinational trials; issues related to multiple trial
analysis, such as Bayesian learning designs, pooling
of clinical trial data, or meta-analysis; design and
analysis in trials where outcomes are valued in mon-
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etary units (i.e., willingness-to-pay studies); meth-
ods for projecting trial ﬁndings; appropriate
methods for a priori selection of items of resource
use to be included in trial protocols (e.g., whether to
include outpatient services, nonstudy drugs); and
selecting levels of aggregation of resources neces-
sary for discriminating between intervention and
control (e.g., counts of hospitalizations vs. length of
stay). As these methods are identiﬁed and validated,
they will be included in future versions of this guid-
ance document.
Source of ﬁnancial support: Support for this project was
provided by ISPOR.
References
1 Weinstein MC, O’Brien B, Hornberger J, et al.
Principles of good practice for decision-analytic
modeling in health-care evaluation: report of the
ISPOR Task Force on Good Research Practices—
Modeling Studies. Value Health 2003;6:9–17.
2 Schwartz D, Lellouch J. Explanatory and prag-
matic attitudes in therapeutical trials. J Chronic
Dis 1967;20:637–48.
3 O’Brien B. Economic evaluation of pharmaceuti-
cals: Frankenstein’s monster or vampire of trials?
Med Care 1996;34:DS99–108.
4 Peto R, Collins R, Gray R. Large-scale rand-
omized evidence: large, simple trials and over-
views of trials. J Clin Epidemiol 1995;48:23–40.
5 Laska EM, Meisner M, Siegel C. Power and sam-
ple size in cost-effectiveness analysis. Med Decis
Making 1999;19:339–43.
6 Briggs A, Tambour M. The design and analysis of
stochastic cost-effectiveness studies for the evalu-
ation of health care interventions. Drug Inf J
2001;35:1455–68.
7 Al MJ, van Hout B, Michel BC, Rutten FF. Sam-
ple size calculation in economic evaluations.
Health Econ 1998;7:327–35.
8 Gardner MJ, Altman DG. Estimation rather
than hypothesis testing: conﬁdence intervals
rather than P values. In: Gardner MJ, Altman
DG, eds., Statistics with Conﬁdence. London:
BMJ, 1989.
9 Luce BR, Manning WG, Siegel JE, et al. Estimat-
ing costs in cost-effectiveness analysis. In: Gold
MR, Siegel JE, Russell LB, et al., eds., Cost-
Effectiveness in Health and Medicine. New York:
Oxford University Press, 1996.
10 Schulman KA, Glick H, Buxton M, et al. The eco-
nomic evaluation of the FIRST study: design of a
prospective analysis alongside a multinational
phase III clinical trial. Flolan International Ran-
domized Survival Trial. Control Clin Trials 1996;
17:304–15.
11 Garber AM, Weinstein MC, Torrance GW,
Kamlet MS. Theoretical foundations of cost-
effectiveness analysis. In: Gold MR, Siegel JE,
Russell LB, et al., eds., Cost-Effectiveness in
Health and Medicine. New York: Oxford Univer-
sity Press, 1996.
12 Ramsey SD, McIntosh M, Sullivan SD. Design
issues for conducting cost-effectiveness analyses
alongside clinical trials. Annu Rev Public Health
2001;22:129–41.
13 Raikou M, Briggs A, Gray A, McGuire A. Centre-
speciﬁc or average unit costs in multi-centre stud-
ies? Some theory and simulation. Health Econ
2000;9:191–8.
14 Reed SD, Friedman JY, Gnanasakthy A,
Schulman KA. Comparison of hospital costing
methods in an economic evaluation of a multina-
tional clinical trial. Int J Technol Assess Health
Care 2003;19:396–406.
15 Coyle D, Drummond MF. Analyzing differences
in the costs of treatment across centers within
economic evaluations. Int J Technol Assess
Health Care 2001;17:155–63.
16 Drummond MF, O’Brien BJ, Stoddart GL,
Torrance GW. Methods for the Economic Evalu-
ation of Health Care Programmes (2nd ed.).
Oxford: Oxford University Press, 1997.
17 U.S Diagnosis Related Group Weights. Available
from: http://www.cms.hhs.gov/providers/hipps/
ippspufs.asp [Accessed February 1, 2005].
18 U.S. National Physician Fee Schedule. Available
from: http://cms.hhs.gov/providers/pufdownload/
rvudown.asp [Accessed February 1, 2005].
19 NHS Reference Costs 2003 and National Tariff
2004  (“Payment  by  Results  Core  Tools




UzhHA3 [Accessed February 1, 2005].
20 Australian Hospital Information, Performance
Information Program. Round 6 National Hospi-
tal Cost Data Collection Cost Weights. Available
from: http://www.health.gov.au/internet/wcms/
Publishing.nsf/Content/health-casemix-costing-fc_
r6.htm [Accessed February 1, 2005].
21 Glick HA, Orzol SM, Tooley JF, et al. Design and
analysis of unit cost estimation studies: how
many hospital diagnoses? How many countries?
Health Econ 2003;12:517–27.
22 Drummond MF, Bloom BS, Carrin G, et al. Issues
in the cross-national assessment of health tech-
nology. Int J Technol Assess Health Care 1992;
8:671–82.
23 Schulman KA, Buxton M, Glick H, et al. Results
of the economic evaluation of the FIRST study: a
multinational prospective economic evaluation.
Int J Technol Assess Health Care 1996;12:698–
713.
ISPOR RCT-CEA Task Force Report 531
24 Dolan P. Modeling valuations for EuroQol health
states. Med Care 1997;35:1095–108.
25 Euroqol Group. EuroQol—a new facility for the
measurement of health-related quality of life. The
Euroqol Group. Health Policy 1990, 1992;16:
199–208.
26 Torrance GW, Zhang Y, Feeny D, et al. Multi-
attribute preference functions for a comprehen-
sive health status classiﬁcation system. Working
Paper No. 92–18. Hamilton, Ontario: McMaster
University Centre for Health Economics and Pol-
icy Analysis.
27 Torrance GW, Boyle MH, Horwood SP. Applica-
tion of multi-attribute utility theory to measure
social preferences for health states. Oper Res
1982;30:1043–69.
28 Feeny D, Furlong W, Torrance GW, et al. Multi-
attribute and single-attribute utility functions for
the health utilities index mark 3 system. Med
Care 2002;40:113–28.
29 Torrance GW, Feeny DH, Furlong WJ, et al.
Multi-attribute utility function for a comprehen-
sive health status classiﬁcation system. Health
Utilities Index Mark 2. Med Care 1996;34:702–
22.
30 Kaplan RM, Anderson JP. A general health policy
model: update and applications. Health Serv Res
1988;23:203–35.
31 Gold MR, Patrick DL, Torrance GW, et al. Iden-
tifying and valuing outcomes in cost-effectiveness
analysis. In: Gold MR, Siegel JE, Russell LB, et
al., eds., Cost-Effectiveness in Health and Medi-
cine. New York: Oxford University Press, 1996.
32 Calvert MJ, Freemantle N. Use of health-related
quality of life in prescribing research. Part 2:
methodological considerations for the assessment
of health-related quality of life in clinical trials. J
Clin Pharm Ther 2004;29:85–94.
33 Sumner W, Nease R, Littenberg B. U-titer: a
utility assessment tool. In: Clayton PD. ed., Pro-
ceedings of the Fifteenth Annual Symposium on
Computer Applications in Medical Care, pp.
701–705. Washington, DC: McGraw Hill, 1991.
34 Hollingworth W, Deyo RA, Sullivan SD, et al.
The practicality and validity of directly elicited
and SF-36 derived health state preferences in
patients with low back pain. Health Econ 2002;
11:71–85.
35 Souchek J, Stacks JR, Brody B, et al. A trial for
comparing methods for eliciting treatment prefer-
ences from men with advanced prostate cancer:
results from the initial visit. Med Care 2000;
38:1040–50.
36 Woloshin S, Schwartz LM, Moncur M, et al.
Assessing values for health: numeracy matters.
Med Decis Making 2001;21:382–90.
37 Katz JN, Phillips CB, Fossel AH, Liang MH. Sta-
bility and responsiveness of utility measures. Med
Care 1994;32:183–8.
38 Salafﬁ F, Stancati A, Carotti M. Responsiveness
of health status measures and utility-based meth-
ods in patients with rheumatoid arthritis. Clin
Rheumatol 2002;21:478–87.
39 Tsevat J, Goldman L, Soukup JR, et al. Stability
of time-tradeoff utilities in survivors of myocar-
dial infarction. Med Decis Making 1993;13:161–
5.
40 Verhoeven AC, Boers M, van Der Linden S.
Responsiveness of the core set, response criteria,
and utilities in early rheumatoid arthritis. Ann
Rheum Dis 2000;59:966–74.
41 Barber JA, Thompson SG. Analysis and inter-
pretation of cost data in randomised controlled
trials: review of published studies. BMJ 1998;
317:1195–200.).
42 O’Hagan A, Stevens JW. Assessing and compar-
ing costs: how robust are the bootstrap and meth-
ods based on asymptotic normality? Health Econ
2003;12:33–49.
43 Thompson SG, Barber JA. How should cost data
in pragmatic randomised trials be analysed? BMJ
2000;320:1197–9.
44 Briggs A, Gray A. The distribution of health care
costs and their statistical analysis for economic
evaluation. J Health Serv Res Policy 1998;3:233–
45.
45 Efron B, Tibshirani R. An Introduction to the
Bootstrap. New York: Chapman and Hall, 1993.
46 Desgagne A, Castilloux AM, Angers JF, et al. The
use of the bootstrap statistical method for the
pharmacoeconomic cost analysis of skewed data.
Pharmacoeconomics 1998;13:487–97.
47 Briggs AH, Gray AM. Handling uncertainty
when performing economic evaluation of health
care interventions. Health Technol Assess 1999;
3:1–134.
48 Barber JA, Thompson SG. Analysis of cost data in
randomized trials: an application of the non-
parametric bootstrap. Stat Med 2000;19:3219–
36.
49 Briggs A, Clarke P, Polsky D, Glick H. Modelling
the cost of health care interventions. Paper pre-
pared for DEEM III: Costing Methods for Eco-
nomic Evaluation. University of Aberdeen, April
15–16, 2003.
50 Manning WG. The logged dependent variable,
heteroscedasticity, and the retransformation
problem. J Health Econ 1998;17:283–95.
51 Manning WG, Mullahy J. Estimating log models:
to transform or not to transform? J Health Econ
2001;20:461–94.
52 Bland JM, Altman DG. The use of transformation
when comparing two means. BMJ 1996;312:
1153.
53 Bland JM, Altman DG. Transformations, means,
and conﬁdence intervals. BMJ 1996;312:1079.
54 Bland JM, Altman DG. Transforming data. BMJ
1996;312:770.
Ramsey et al.532
55 White IR, Thompson SG. Choice of test for com-
paring two groups, with particular application to
skewed outcomes. Stat Med 2003;22:1205–15.
56 Hosmer DW Jr, Lemeshow S. Applied Survival
Analysis. New York: John Wiley & Sons, 1999.
57 Kalbﬂeish JD, Prentice RL. The Statistical Analy-
sis of Failure Time Data. New York: John Wiley
& Sons, 1980.
58 Davidson R, MacKinnon JG. Estimation and
Inference in Econometrics. New York: Oxford
University Press, 1993.
59 Hosmer DW Jr, Lemeshow S. Applied Logistic
Regression (2nd ed.). New York: John Wiley &
Sons, 2003.
60 Winer BJ, Brown DR, Torrie JH. Statistical Prin-
ciples in Experimental Design (3rd ed.). New
York: McGraw-Hill, 1991.
61 Patrick DL, Erickson P. Chapter 11, Ranking
costs and outcomes of health care alternatives.
In: Health Status and Health Policy: Quality of
Life in Health Care Evaluation and Resource
Allocation. New York: Oxford University Press,
1993.
62 Sharma R, Stano M, Hass M. Adjusting to
changes in health: implications for cost-effective-
ness analysis. J Health Econ 2004;23:335–51.
63 Austin PC. A comparison of methods for analyz-
ing health-related quality of life measures. Value
Health 2002;4:329–37.
64 Gray SM, Brookmeyer R. Estimating a treatment
effect from multidimensional longitudinal data.
Biometrics 1998;54:976–88.
65 Hedeker D, Gibbons RD. Application of random
effects pattern-mixture models for missing data in
longitudinal studies. Pyschol Methods 1997;2:
64–78.
66 Little RJA, Rubin DB. Statistical Analysis with
Missing Data. New York: John Wiley & Sons,
1987.
67 Rubin DB. Multiple Imputation for Nonresponse
in Surveys. New York: John Wiley, 1987.
68 Briggs A, Clark T, Wolstenholme J, Clarke P.
Missing . . . presumed at random: cost-analysis of
incomplete data. Health Econ 2003;12:377–92.
69 Schafer JL. Multiple imputation: a primer. Stat
Methods Med Res 1999;8:3–15.
70 Horton NJ, Lipsitz SR. Multiple imputation in
practice: comparison of software packages for
regression models with missing variables. Am
Statistician 2001;55:244–54.
71 Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating
medical costs from incomplete follow-up data.
Biometrics 1997;53:419–34.
72 Bang H, Tsiatis AA. Median regression with cen-
sored cost data. Biometrics 2002;58:643–9.
73 Etzioni RD, Feuer EJ, Sullivan SD, et al. On the
use of survival analysis techniques to estimate
medical care costs. J Health Econ 1999;18:365–
80.
74 Carides GW, Heyse JF, Iglewicz B. A regression-
based method for estimating mean treatment cost
in the presence of right-censoring. Biostatistics
2000;1:299–313.
75 O’Hagan A, Stevens JW. On estimators of medi-
cal costs with censored data. J Health Econ
2004;23:615–25.
76 Raikou M, McGuire A. Estimating medical care
costs under conditions of censoring. J Health
Econ 2004;23:443–70.
77 Stinnett AA, Mullahy J. Net health beneﬁts: a new
framework for the analysis of uncertainty in cost-
effectiveness analysis. Med Decis Making 1998;
18(Suppl. 2):S68–80.
78 Tambour M, Zethraeus N, Johannesson M. A
note on conﬁdence intervals in cost-effectiveness
analysis. Int J Technol Assess Health Care 1998;
14:467–71.
79 Willan AR, Lin DY. Incremental net beneﬁt in
randomized clinical trials. Stat Med 2001;20:
1563–74.
80 Van Hout BA, Al MJ, Gordon GS, Rutten FFH.
Costs, effects and C/E-ratios alongside a clinical
trial. Health Econ 1994;3:309–19.
81 Fenwick E, Claxton K, Sculpher M. Representing
uncertainty: the role of cost-effectiveness accept-
ability curves. Health Econ 2001;10:779–87.
82 O’Brien BJ, Drummond MF, Labelle RJ, Willan
A. In  search  of  power  and  signiﬁcance:  issues
in the design and analysis of stochastic cost-
effectiveness studies in health care. Med Care
1994;32:150–63.
83 Chaudhary MA, Stearns SC. Estimating conﬁ-
dence intervals for cost-effectiveness ratios: An
example from a randomized trial. Stat Med
1996;15:1447–8.
84 Gold MR, Siegel JE, Russell LB, Weinstein M.
Cost-Effectiveness in Health and Medicine. New
York: Oxford University Press, 1996.
85 O’Brien BJ. A tale of two or more cities: geo-
graphic transferability of pharmacoeconomic
data. Am J Man Care 1997;3(Suppl.):S33–9.
86 Schulman K, Burke J, Drummond M, et al.
Resource costing for multinational neurologic
clinical trials: methods and results. Health Econ
1998;7:629–38.
87 Koopmanschap MA, Touw KCR, Rutten FFH.
Analysis of costs and cost-effectiveness in multi-
national trials. Health Policy 2001;58:175–86.
88 Gosden TB, Torgerson DJ. Converting inter-
national cost-effectiveness data to UK prices.
BMJ 2002;325:275–6.
89 Sullivan SD, Liljas B, Buxton MJ, et al. Design
and analytic considerations in determining the
cost-effectiveness of early intervention in asthma
from a multinational clinical trial. Control Clin
Trials 2001;22:420–37.
90 Buxton MJ, Sullivan SD, Andersson FL, et al.
Country-speciﬁc cost-effectiveness of early inter-
ISPOR RCT-CEA Task Force Report 533
vention with budesonide in mild asthma. Eur
Respir J 2004;24:568–74.
91 Gerdtham UG, Jönsson B. Conversion factor
instability in international comparisons of health
care expenditure. J Health Econ 1991;10:227–
34.
92 World Bank. World Development Indicators
2001. Washington, DC: The World Bank,
2001.
93 Willke RJ, Glick HA, Polsky D, Schulman K.
Estimating country-speciﬁc cost-effectiveness
from multinational clinical trials. Health Econ
1998;7:481–93.
94 Barbieri M, Drummond M, Willke R, et al.
Variability of cost-effectiveness estimates for
pharmaceuticals in Western Europe: lessons for
inferring generalizability. Value Health 2005;
8:10–23.
95 Jönsson B, Weinstein M. Economic evaluation
alongside multinational clinical trials: study con-
siderations for GUSTO IIb. Int J Technol Assess
Health Care 1997;13:49–58.
96 Cook JR, Drummond M, Glick H, Heyse JF.
Assessing the appropriateness of combining
economic data from multinational clinical trials.
Stat Med 2003;22:1955–76.
97 Wordsworth S, Ludbrook A. Comparing costing
results in across country evaluations: the use of
technology speciﬁc purchasing power parity esti-
mates. Health Econ 2005;14:93–9.
98 Meltzer D. Accounting for future costs in medical
cost-effectiveness analysis. J Health Econ 1997;
16:33–64.
99 Drummond MF, Jefferson TO, for the BMJ
Working Party on Guidelines for Authors and
Peer-Reviewers of Economic Submissions to the
British Medical Journal. Guidelines for authors
and peer-reviewers of economic submissions to
the British Medical Journal. BMJ 1996;313:275–
383.
100 Siegel JE, Weinstein MC, Russell LB, Gold MR.
Recommendations for reporting cost-effectiveness
analyses. Panel on Cost-Effectiveness in Health
and Medicine. JAMA 1996;276:1339–4.
